A New Regimen in the Treatment of Psoriasis Using Oral Methotrexate
- 1 Department of Dermatology, College of Medicine, University of Baghdad, Baghdad, Iraqi
- 2 Center of Dermatology and Venereology, Medical City, Baghdad, Iraq
- 3 Center of Dermatology and Venereology, Medical City, Baghdad, Iraq
Abstract
Background: Methotrexate is a well-known standard therapy for psoriasis. The standard regimen is using six (2.5 mg) tablets/week that might be with many side effects. Objective: Finding a new regimen for oral methotrexate aiming to decrease side effects and increase its effectiveness. Patients and Methods: This therapeutic, comparative study done at the Center of Dermatology, Medical city, from October 2017 to October 2018. Fifty-three patients with moderate to severe psoriasis completed the study. They were divided into: Group (A) (27) patients were treated with the new oral regimen and Group (B) (26) patients were treated with the six tablets/week. Investigations including CBC, LFT and RFT were done. PASI score, BSA and side effects especially gastrointestinal ones were recorded. Results: They were 29 males and 24 females. Age ranged from 18 - 67 years. Disease duration ranged from 1 - 30 years. BSA involved ranged from 20% - 79%. The PASI score ranged from 10.2 - 45.7. After 8 weeks of treatment, there was statistically significant difference (p-value > 0.001) regarding PASI score and gastrointestinal side effects being less in Group (A). Group A patients were more satisfied. Conclusion: The new regimen used in the present study has lower gastrointestinal side effects and more efficacy.
- Burden, A.D. and Kirby, B. (2016) Psoriasis and Related Disorders. In: Griffiths, C., Barker, J., Bleiker, T., Chalmers, R. and Creamer, D., Eds., Rook’s Textbook of Dermatology, 9th Edition, John Wiley & Sons, New Delhi, 1-48. https://doi.org/10.1002/9781118441213
- Gudjonsson, J.E. and Elder, J.T. (2012) Psoriasis. In: Wolff, K., Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S. and Leffell, D.J., Eds., Fitzpatrick’s Dermatology in General Medicine, 8th Edition, The McGraw-Hill Companies, Singapore, 197-231. https://doi.org/10.1111/j.1524-4725.2008.34211.x
- Bowcock, A.M. and Krueger, J.G. (2005) Getting under the Skin: The Immunogenetics of Psoriasis. Nature Reviews Immunology, 5, 699-711.
- Jeffes III, E.W.B., McCullough, J.L. and Pittelkow, M.R. (1995) Methotrexate Therapy of Psoriasis. Differential Sensitivity of Proliferating Lymphoid and Epithelial Cells to the Cytotoxic and Growth-Inhibitory Effects of Methotrexate. Journal of Investigative Dermatology, 104, 183-188. https://doi.org/10.1111/1523-1747.ep12612745
- Sigmundsdottir, H., Johnston, A. and Gudjonsson, J.E. (2004) Methotrexate Markedly Reduces the Expression of Vascular E-Selectin, Cutaneous Lymphocyte-Associated Antigen and the Numbers of Mononuclear Leucocytes in Psoriatic Skin. Experimental Dermatology, 13, 426-434. https://doi.org/10.1111/j.0906-6705.2004.00177.x
- Callen, J.P. and Kulp-Shorten, C.L. (2012) Methotrexate. In: Wolverton, S.E., Ed., Comprehensive Dermatologic Drug Therapy, 3rd Edition, Elsevier Inc., London, 169-181.
- Weinstein, G.D. and Frost, P. (1971) Methotrexate for Psoriasis: A New Therapeutic Schedule. Archives of Dermatology, 103, 33-38. https://doi.org/10.1001/archderm.103.1.33
- https://www.dermnetnz.org/topics/pasi-score/
- Lomholt, G. (1963) Psoriasis: Prevalence, Spontaneous Course and Genetics. GEC Gad, Copenhagen, 78-189.
- Warren, R.B., Chalmers, R.J.G., Griffiths, C.E.M. and Menter, A. (2008) Methotrexate for Psoriasis in the Era of Biological Therapy. Clinical and Experimental Dermatology, 33, 551-554. https://doi.org/10.1111/j.1365-2230.2008.02976.x
- Menting, S.P., Dekker, P.M., Limpens, J., Hooft, L. and Spuls, P.I. (2016) Methotrexate Dosing Regimen for Plaque-Type Psoriasis: A Systematic Review of the Use of Test-Dose, Start-Dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. Acta Dermato-Venereologica, 96, 23-29. https://doi.org/10.2340/00015555-2081